Given the large number of stroke cases in the US, future research will need to identify which demographic characteristics and lifestyles contribute to stroke risk.
Symptoms can be broken into 3 main groups; acute, sub-acute and chronic. The acute stroke syndrome is associated with unilateral symptoms; however, the sub-acute and chronic stroke syndromes are associated with bilateral symptoms.
Stroke is a medical emergency that requires immediate, effective treatment. Stroke causes major losses of life, disability, and economic costs. Every second stroke results in disability, and every second stroke (and stroke survivor) may die.
A number of possible causes of stroke have been reviewed. Theories of the causes of stroke have implications for the development of stroke prevention and treatment. These include the traditional risk factors and non-traditional risk factors.
Given that the disease is a process not a static condition, that its effects vary over time and are dependent on the specific individual's circumstances and response, that its course may be very different from that of other diseases, and that more effective methods have been recommended, it seems that the possibility of a cure is extremely remote.
Common treatments for stroke include antiplatelet agents such as aspirin and clopidogrel, and statin for prevention of cardiovascular disease. Beta-blockers and carotid endarterectomy may be helpful for preventing recurrent stroke. Exercise and physical therapy are often recommended for stroke. There is no known cure for stroke.\n
There were no associations between genetic markers and stroke risk. No evidence has shown that stroke is influenced by a genetic profile and familial relationships. Nevertheless, the results point to the need to study genetic influences in populations at risk even if the gene(s) responsible have not yet been identified.
The main cause of stroke in this study was atherosclerosis. The primary risk factor for atherosclerosis is age. It has been demonstrated that people of every age suffer from stroke but people who are younger than 40 have disproportionately high rates of stroke, even after adjustment for atherosclerosis and other risk factors. People who are older than 40 have the second highest rates of stroke after those who have high cholesterol levels. People with hypertension may have a greater risk of a hemorrhagic stroke than individuals without hypertension. Blood pressure control is a top priority in prevention of strokes in both young and aging populations. The relative risks of stroke vary according to the age groups in which it occurs.
Most recent advances in the treatment of stroke have been made by the medical communities from research in the treatment of other conditions. These advances are not new discoveries in stroke research, but rather applying existing, known treatments more correctly and efficiently in this particular disease. The advances are discussed together with the limitations of these interventions with respect to the treatment of stroke.
It appears that maraviroc has been used in HIV/HCV-coinfected patients to treat HCMV infections. The first case report of maraviroc being used for this indication was published in 2000. The FDA approved maraviroc for use as a HCV treatment in 2004. As a result of this, it is also likely to be the most-widely used candidate for HCMV treatment until much more evidence becomes available.
It is easy to find the pictures on media and in books and movies to show what is the effect of stroke and what is being done to reverse it. For patients, that looks like a miracle. It is hard to tell, without getting there myself, how far can we go. I don’t think that any of us are quite sure what is happening when we suffer stroke. But as far as we know, that is more or less the case with what we are told about the effects of stroke by health and stroke societies.
Maraviroc is in late stage phase II/III clinical development for the treatment of HIV infection. Thus, the use of this drug would be limited to salvage therapy for patients with HIV infection who have acquired multidrug-resistant HIV and HIV/HIV co-infection following failed use of therapy.